The Vienna-based healthtech startup XUND has raised €6 million in a seed funding to expand to new European and US markets. The round was co-led by MMC Ventures and MassMutual Ventures, Tech.eu informs.
- Founded in 2018 by Lukas Seper, Tamas Petrovics, Zoltan Tarabo, XUND is a B2B healthtech that develops medical API product and provides symptom and risk assessment capabilities for healthcare companies. Using AI, XUND medical database analyses millions of medical publications to make a healthcare decisions.
- XUND API is certified as a medical device, with the main idea to offer patients an initial assessment and guide them to a place for treatment.
“Our ambition is to eventually cover the entire patient lifecycle from prevention over diagnosis to treatment and monitoring, allowing XUND to become the central infrastructure provider for digital patient interactions across insurance, pharma, digital and in-person healthcare,”
commented Tamas Petrovics, co-founder and CEO of XUND.
- The fresh seed round was led by two funds — UK early-stage investor MMC Ventures, that supports e-commerce, fintech, and digital health startups, and US multi-stage, global VC firm MassMutual Ventures that invests in enterprise software, cybersecurity, financial technology, and digital health. RoX Health (Roche), and LANA Ventures also participated in the funding.
- XUND will spend the fresh funds to expand operations outside the DACH region, including both new European markets and a US market entry.
